Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Blood (2025) 146 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2025-1841

Published: 2025

Journal Articles

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Yun Kyoung Tiger, Roshan Asrani, Graham Wehmeyer, Robert Ryan, Ajay Major, Natalie Grover, Kelsey Baron, Talal Hilal, Adrienne Nedved, Taylor Brooks, Arjun Ravishankar, Tarsheen Sethi, Brian Hill, Yucai Wang, Allison Bock, Adam Kittai, Matthew Matasar, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2025-1956

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Blood (2025) 146 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2025-3885

Published: 2025

Journal Articles

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Joanna Rhodes, Adam Kittai, Paul Hampel, Xiaoliang Wang, Qianhong Fu, Danni Zhao, Smriti Karwa, Olive Mbah, Ahmed Sawas, Benjamin Wagner, Rachel Myers, Derrick van Beuge, Gregory Maglinte, Erlene Seymour, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2025-2720

Published: 2025

Journal Articles

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Blood (2025) 146 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2025-3622

Published: 2025

Journal Articles

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Blood (2025) 146 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2025-3617

Published: 2025

Journal Articles

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Mengyang Di, Xiaoliang Wang, Qianhong Fu, Dong Yuan, Gregory Maglinte, Erlene Seymour, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 6283.

https://doi.org/10.1182/blood-2025-6283

Published: 2025

Journal Articles

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 784.

https://doi.org/10.1182/blood-2025-784

Published: 2025

Journal Articles

Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)

Blood (2025) 146 (Supplement 1): 568.

https://doi.org/10.1182/blood-2025-568

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings

Blood (2018) 132 (Supplement 1): 4410.

https://doi.org/10.1182/blood-2018-99-118159

Published: 2018

Journal Articles

Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients

Joanna Rhodes, MD, Anthony R. Mato, MD MSCE, Nicole Winchell, Kaitlin Kennard, RN, BSN, James Nathan Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2018-99-115377

Published: 2018

Journal Articles

Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients

Blood (2018) 132 (Supplement 1): 3142.

https://doi.org/10.1182/blood-2018-99-114840

Published: 2018

Journal Articles

Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study

Blood (2018) 132 (Supplement 1): 4759.

https://doi.org/10.1182/blood-2018-99-119015

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration

Blood (2018) 132 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2018-99-113173

Published: 2018

Journal Articles

Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies

Anthony R. Mato, MD, John N. Allan, MD, John M. Pagel, MD PhD, Danielle M. Brander, MD, Brian T. Hill, MD PhD, Bruce D. Cheson, MD, Richard R. Furman, MD, Nicole Lamanna, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Ryan Jacobs, MD, Frederick Lansigan, MD, Paul M. Barr, MD, Mazyar Shadman, MD, Alan P Skarbnik, MD, Douglas F. Beach, MD, Jeffrey J. Pu, MD PhD, Alison R. Sehgal, MD, Allison M. Winter, MD, Clive S Zent, MD, Hande H. Tuncer, MD, Arun K Singavi, MD, Stephen J. Schuster, MD, Peter V. Pickens, MD, Nirav N Shah, MD, Annalynn Williams, MS, Christina Howlett, PharmD, BCOP, Hanna Weissbrot, BS, Naveed Ali, MD, Bhavisha Patel, MD, Krista Isaac, DO, MS, Joanna Rhodes, MD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Sirin Khajavian, MD, Elizabeth T Chatburn, BS, Andrea Sitlinger, MD, Eve Tranchito, BS, Erica Bharat Bhavsar, BS, Neil Bailey, MS, Timothy F. Burns, MD, Melissa Yacur, MD, Mansi Malhotra, BS, Sasanka Handunnetti, MD, Kaitlin Kennard, RN, BSN, Chadi Nabhan, MD MBA, FACP, Chaitra S. Ujjani, MD

Blood (2017) 130 (Supplement 1): 3011.

https://doi.org/10.1182/blood.V130.Suppl_1.3011.3011

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings

Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients

Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients

Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study

Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration

Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only